Cargando…
Immunogenetics of glioblastoma: the future of personalized patient management
The prognosis of glioblastoma has changed little over the past two decades, with only minor improvements in length of overall survival through the addition of temozolomide (temodal) to standard of care and the recommended use of alternating electric field therapy (optune) to newly diagnosed patients...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279755/ https://www.ncbi.nlm.nih.gov/pubmed/30534602 http://dx.doi.org/10.1038/s41698-018-0070-1 |